Salix price target raised to $125 from $108 at Brean Capital

Brean Capital raised its price target on Salix following Q4 results. The firm is citing upcoming catalysts including a PDUFA date for its drug candidate for acute attacks of angioedema and its acquisition of the worldwide rights to Red Hill's drug formulation for bowel preparation. Shares are Buy rated.

View Comments (0)